Corticotropin-releasing hormone receptor (type I) antisense targeting reduces anxiety

Neuroscience

Volumn 85, Issue 3, 1998, Pages 795-805

  Skutella, T ^a   Probst, J C ^a   Renner, U ^a   Holsboer, F ^a   Behl, C ^a  

^a MAX PLANCK INSTITUTE OF PSYCHIATRY   (Germany)

Author keywords

Adenocorticotrophic hormone; Antisense oligodeoxynucleotides; Anxiety; Corticotropin releasing hormone; Corticotropin releasing hormone receptor; Stress

Indexed keywords

ANTISENSE OLIGODEOXYNUCLEOTIDE; CORTICOTROPIN; CORTICOTROPIN RELEASING FACTOR RECEPTOR; MESSENGER RNA;

ADENOHYPOPHYSIS; ANIMAL BEHAVIOR; ANIMAL CELL; ANXIETY NEUROSIS; ARTICLE; CELL SURVIVAL; HISTOLOGY; MAZE TEST; NONHUMAN; PRIORITY JOURNAL; RAT;

ADRENOCORTICOTROPIC HORMONE; ANIMALS; ANTISENSE ELEMENTS (GENETICS); ANXIETY; CELL SURVIVAL; CEREBELLUM; CEREBRAL CORTEX; CORTICOTROPIN-RELEASING HORMONE; FEAR; HYPOTHALAMUS; MALE; MAZE LEARNING; MICE; PITUITARY GLAND; PITUITARY NEOPLASMS; RADIOLIGAND ASSAY; RATS; RATS, WISTAR; RECEPTORS, CORTICOTROPIN-RELEASING HORMONE; RNA, MESSENGER; STRESS, PSYCHOLOGICAL; TUMOR CELLS, CULTURED;

EID: 0031925646     PISSN: 03064522     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0306-4522(97)00682-9     Document Type: Article

References (46)

1. Auernhammer G. J., Renner U., Müller O.-A., Stalla J., Stalla G. K. Loperamide inhibits corticotrophic cell function by a naloxone-insensitive mechanism in the rat in vitro. Neuroendocrinology. 57:1993;1019-1027.
2. Behl C., Davis J. B., Lesley R., Schubert D. Hydrogen peroxide mediates amyloid β protein toxicity. Cell. 77:1994;817-827.
3. Bilezikjian L. M., Vale W. W. Glucocorticoids inhibit corticotropin-releasing factor-induced production of adenosine 3′, 5′-monophosphate in cultured anterior pituitary cells. Endocrinology. 113:1983;657-662.
4. Britton D. R., Britton K. T. A sensitive open field measure of anxiolytic drug activity. Pharmac. Biochem. Behav. 15:1981;577-582.
5. DeSouza E. B., Perrin M. H., Rivier J. H., Vale W. W., Kuhar M. J. Corticotropin-releasing factor receptors in rat pituitary gland: autoradiographic localization. Brain Res. 296:1984;202-207.
6. DeSouza E. B., Insel T. R., Perrin M. H., Rivier J., Vale W. W., Kuhar M. J. Corticotropin-releasing factor receptors are widely distributed within the rat central nervous system. An autoradiographic study. J. Neurosci. 5:1985;3189-3203.
7. Dunn A. J., Berridge C. W. Physiological and behavioral response to corticotropin-releasing factor administration: is CRF a mediator of anxiety or stress response? Brain Res. Rev. 15:1990;71-100.
8. File S., Johnston A. L., Baldwin H. A. Anxiolytic and anxiogenic drugs: changes in behavior and endocrine responses. Stress Med. 4:1988;221-230.
9. Gibbs D. M., Steward R. D., Vale W. W., Rivier J., Yen S. S. C. Synthetic corticotropin-releasing factor stimulates secretion of immunoreactive beta-endorphin/beta-lipoprotein and ACTH by human fetal pituitaries in vitro. Life Sci. 32:1982;547-550.
10. Grossman A., Perry L., Schally A. V., Rees L. H., Nieuwenhuyzen-Krusem A. C., Tomlin S., Coy D. H., Comaru-Schally A. M., Besser G. M. New hypothalamic hormone, corticotropin-releasing factor, specifically stimulates the release of adrenocorticotropic hormone and cortisol in man. Lancet. 1:1982;921-922.
11. Hansen M. B., Nielsen S. E., Berg K. Re-examination and further development of a precise and rapid dye method for measuring cell growth/cell killing. J. immun. Meth. 119:1989;203-210.
12. Holsboer F., Spengler D., Heuser I. The role of corticotropin-releasing hormone in the pathogenesis of Cushing's disease, anorexia nervosa, alcoholism, affective disorders and dementia. Prog. Brain Res. 93:1992;385-417.
13. Kalin N. H. (1990) In Corticotropin-Releasing Factor: Basic and Clinical Studies of a Neuropeptide (eds DeSouza E. B. and Nemeroff C. B.), pp. 275-290, CRC, Boca Raton.
14. Lovenberg T. W., Liaw C. W., Grigoriadis D. E., Clevenger W., Chalmers D. T., DeSouza E. B., Oltersdorf T. Cloning and characterization of a functionally distinct corticotropin-releasing factor receptor subtype from rat brain. Proc. natn. Acad. Sci. U.S.A. 92:1995;836-840.
15. McCarthy M. M., Kleopoulos S. P., Mobbs C. V., Pfaff D. W. Infusion of antisense oligodeoxynucleotides to the oxytocin receptor in the ventromedial hypothalamus reduces estrogen-induced sexual receptivity and oxytocin receptor binding in the female rat. Neuroendocrinology. 59:1994;432-440.
16. Meeker R., LeGrand G., Ramirez J., Smith T., Shih Y.-H. Antisense vasopressin oligonucelotides: uptake, turnover, distribution, toxicity and behavioral effects. J. Neuroendocr. 7:1995;419-428.
17. Meunier H., Lefevre G., Dumont D., Labrie F. CRF stimulates alpha-MSH secretion and cyclic AMP accumulation in pars intermedia cells. Life Sci. 31:1982;2129-2135.
18. Neumann I., Porter D. W. F., Landgraf R., Pittman Q. J. Rapid effect on suckling of an oxytocin antisense oligonucleotide administered into the rat supraoptic nucleus. Am. J. Physiol. 267:1994;852-858.
19. Owens M. J., Nemeroff C. B. Physiology and pharmacology of corticotropin-releasing factor. Pharmac. Rev. 43:1993;425-473.
20. Owens M. J., Mulchahey J. J., Kasckow J. W., Plotsky P. M., Nemeroff C. B. Exposure to an antisense oligonucleotide decreases corticotropin-releasing factor receptor binding in rat pituitary cultures. J. Neurochem. 64:1995;2358-2361.
21. Perrin M. H., Donaldson C. J., Chen R., Lewis K. A., Vale W. W. Cloning and functional expression of a rat corticotropin-releasing factor (CRF) receptor. Endocrinology. 133:1986;3058-3061.
22. Potter E., Sutter S., Donaldson C., Chen R., Perrin M., Lewis K., Sawchenko P. E., Vale W. W. Distribution of corticotropin-releasing factor receptor mRNA expression in the rat brain and pituitary. Proc. natn. Acad. Sci. U.S.A. 91:1994;8777-8781.
23. Proulx-Ferland L., Labrie F., Dumont D., Cote J., Coy D. H., Sveiraf J. Corticotropin-releasing factor stimulates secretion of melanocyte-stimulating hormone from the rat pituitary. Science. 217:1982;62-63.
24. Rivier C., Brownstein J., Spiess J., Rivier J., Vale W. W. In vivo corticotropin-releasing factor-induced secretion of adrenocorticotropin, beta-endorphin, and corticosterone. Endocrinology. 110:1982;272-278.
25. Sakai R. R., He P. F., Yang X. D., Ma L. Y., Guo Y. F., Reilly J. J., Moga C. N., Fluharty S. J. Intracerebroventricular administration of AT1 receptor antisense oligonucleotides inhibits the behavioral actions of angiotensin II. J. Neurochem. 62:1994;2053-2056.
26. Segre G. V., Goldring S. R. Receptors for secretin, calcitonin, parathyroid hormone (PTH)/PTH-related peptide, vasoactive intestinal peptide, glucagonlike peptide 1, growth hormone-releasing hormone, and glucagon belong to a newly discovered G-protein-linked receptor family. Trends endocr. Metab. 4:1993;309-314.
27. Skutella T., Montkowski A., Stöhr T., Probst J. C., Lammers C.-H., Landgraf R., Holsboer F., Jirikowski G. F. Corticotropin-releasing hormone (CRH) antisense oligodeoxynucleotide treatment attenuates social defeat-induced anxiety in rats. Cell. molec. Neurobiol. 14:1994;579-588.
28. Skutella T., Criswell H., Moy S., Probst J. C., Breese G. R., Jirikowski G. F., Holsboer F. Corticotropin-releasing hormone (CRH) antisense oligodeoxy-nucleotide induces anxiolytic effects in rat. NeuroReport. 5:1994;2181-2185.
29. Slater T. F., Sawyer B., Strauli U. Studies of succinate reductase systems III. Points of coupling of four different tetrazolium salts. Biochim. biophys. Acta. 77:1963;383-393.
30. Spiess J., Rivier J., Rivier C., Vale W. W. Primary structure of corticotropin-releasing factor from ovine hypothalamus. Proc. natn. Acad. Sci. U.S.A. 78:1981;6517-6521.
31. Standifer K. M., Chien C.-C., Wahlestedt C., Brown G. P., Pasternak G. W. Selective loss of δ opioid analgesia and binding by antisense oligodeoxynucleotides to a δ opioid receptor. Neuron. 12:1994;805-810.
32. Stein C. A., Cheng Y. C. Antisense oligonucleotides as therapeutic agents - is the bullet really magical? Science. 261:1993;1004-1012.
33. Sutton R. E., Koob G. F., Le Moal M., Rivier J., Vale W. W. Corticotropin-releasing factor (CRF) produces behavioral activation in rats. Nature. 297:1981;331-333.
34. Treit D. Animal models for the study of anti-anxiety agents: a review. Neurosci. Biobehav. Rev. 9:1985;203-223.
35. Vale W. W., Spiess J., Rivier C., Rivier J. Characterization of a 41-residue ovine hypothalamic peptide that stimulates secretion of corticotropin and beta-endorphin. Science. 213:1981;1394-1397.
36. Vita N., Laurent P., Lefort S., Chalon P., Lelias J. M., Kaghad M., Le Fur G., Caput D., Ferrara P. Primary structure and functional expression of mouse pituitary and human brain corticotrophin releasing factor receptors. Fedn Euir. Biochem. Socs Lett. 335:1993;1-5.
37. Wagner R. Gene inhibition using antisense oligodeoxynucleotides. Nature. 372:1994;333-335.
38. Wahlestedt C., Golanov E., Yamamoto S., Yee F., Ericson H., Yoo H., Inturrisi C. E., Reis D. J. Antisense oligonucleotides to NMDA-R1 receptor channel protect cortical neurons from excitotoxicity and reduce focal ischaemic infarctions. Nature. 363:1993;260-263.
39. Wahlestedt C., Pich E. M., Koob G. F., Yee F., Heilig M. Modulation of anxiety and neuropeptide Y-Y1 receptors by antisense oligonucleotides. Science. 259:1993;528-531.
40. Wahlestedt C. Antisense oligonucleotide strategies in neuropharmacology. Trends pharmac. Sci. 15:1994;42-43.
41. Weiss B., Zhou L.-W., Zhang S.-P., Qin Z.-H. Antisense oligodeoxynucleotide inhibits D2 dopamine receptor-mediated behavior and D2 messenger RNA. Neuroscience. 55:1993;607-612.
42. Wong M.-L., Licinio J., Paternak K. I., Gold P. W. Localization of corticotropin-releasing hormone (CRH) receptor mRNA in adult rat brain by in situ hybridization histochemistry. Endocrinology. 135:1994;2275-2278.
43. Wynn P. C., Hauger R. L., Holmes M. C., Millan M. A., Catt K. J., Aguilera G. Brain and pituitary receptors for corticotropin-releasing factor: localization and differential regulation after adrenalectomy. Peptides. 5:1984;1077-1084.
44. Yee F., Ericson H., Reis D. J., Wahlestedt C. Cellular uptake of intracerebroventricularly administered biotin- or digoxigenin-labeled antisense oligonucleotides in the rat. Cell. molec. Neurobiol. 14:1994;475-486.
45. Zhang M., Creese I. Antisense oligonucleotides reduces brain dopamine D2 receptors: behavioral correlates. Neurosci. Lett. 161:1993;223-226.
46. Zhao Q., Matson S., Herrera C. J., Fisher E., Yu H., Krieg A. M. Comparison of cellular binding and uptake of antisense phosphodiester, phosphorothioate, and mixed phosphorothioate and methylphosphonate oligonucleotides. Antisense Res. Dev. 3:1993;53-66.